Clinical Trial Search

Primary: Prefrontal GABA Concentrations Through Proton Magnetic Resonance Spectroscopy — 2.625; 2.696; 2.609; 2.720 Institutional Units — p=0.711

Primary: Number of Participants With Clinical Cure — 20; 33 Participants

Primary: Efficacy of the Dosing Algorithm in Achieving Total 25(OH)D as Measured by the Percentage of Participants Ending With Concentrations of 35-50 ng/mL — 61.3; 58.5; 47.6…

Primary: Metabolic Cost of Walking — 0.409; 0.397 J/Nm — p=0.585

Primary: Change in FEV1 From Pre Dose to End of Treatment — 0.23; 0.22; 0.09 Litres

Primary: Part A: Number of Participants With Dose Limiting Toxicities (DLTs) — 0 Participants

Primary: Response to Therapy — 15; 29 Participants

Primary: Number of Participants With Adverse Events — 08; 01; 02 participants

Primary: All-cause Mortality Rate at Day 14 — 12.4; 11.6 percentage of participants — p=0.0020

Primary: Change From Baseline Amount of Fat Oxidation at 14 Days — 0.91; 0.94 Fold change of RQ ratio

Primary: Change in Behaviorally Coded Challenging Behaviors (Agitated, Disruptive, Resistive) — 784; 253 Care videos submitted

Primary: Overall Survival (OS) — 7.9; 8.6; 9.1; 7.7 Months

Primary: Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale — -13.81; -9.67 units on a scale

Primary: Number of Participants With the Opinion of the Products' Flavor — 1; 0; 0; 0 Participants

Primary: Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline…